0000899243-23-004211.txt : 20230207
0000899243-23-004211.hdr.sgml : 20230207
20230207175049
ACCESSION NUMBER: 0000899243-23-004211
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230203
FILED AS OF DATE: 20230207
DATE AS OF CHANGE: 20230207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ege David S.
CENTRAL INDEX KEY: 0001829360
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37465
FILM NUMBER: 23596381
MAIL ADDRESS:
STREET 1: C/O SERES THERAPEUTICS, INC.
STREET 2: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Seres Therapeutics, Inc.
CENTRAL INDEX KEY: 0001609809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274326290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617 945 9626
MAIL ADDRESS:
STREET 1: 200 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Seres Health, Inc.
DATE OF NAME CHANGE: 20140603
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-02-03
0
0001609809
Seres Therapeutics, Inc.
MCRB
0001829360
Ege David S.
C/O SERES THERAPEUTICS, INC.
200 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
See Remarks
Restricted Stock Units
2023-02-03
4
A
0
47500
0.00
A
Common Stock
47500
47500
D
Stock Option (Right to Buy)
5.50
2023-02-03
4
A
0
95000
0.00
A
2033-02-02
Common Stock
95000
95000
D
Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.
The option will vest as to 25% of the shares on February 3, 2024. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Executive Vice President and Chief Technology Officer
/s/ Thomas J. DesRosier, attorney-in-fact for David S. Ege
2023-02-07